Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist

This article was originally published in The Pink Sheet Daily

Executive Summary

Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.

You may also be interested in...



CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera

Europe's scientific advisory panel recommends Boehringer Ingelheim's Trajenta and Novartis's Votubia for approval, and clears new indications for Amgen's Vectibix.

CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera

Europe's scientific advisory panel recommends Boehringer Ingelheim's Trajenta and Novartis's Votubia for approval, and clears new indications for Amgen's Vectibix.

Caught Between Two Partners: Amylin Seeks To Block Lilly's Byetta Sales Force From Marketing Tradjenta

Amylin claims Lilly has breached its agreement to commercialize exenatide as the Big Pharma gears up to launch the Boehringer-developed diabetes drug Tradjenta.

Related Content

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel